PDF herunterladen
Open Access
CC BY-NC-ND 4.0 · Sleep Sci 2021; 14(01): 27-32
DOI: 10.5935/1984-0063.20190149
Original Article

Treatment of chronic insomnia with atypical antipsychotics: results from a follow-up study

Autor*innen

  • Behnam Khaledi-Paveh

    1   Sleep disorders research center, Kermanshah University of Medical Sciences, Kermanshah, Iran.
    2   School of Nursing and Midwifery, Kermanshah University of Medical Sciences, Kermanshah, Iran.

  • Soroush Maazinezhad

    1   Sleep disorders research center, Kermanshah University of Medical Sciences, Kermanshah, Iran.

  • Leeba Rezaie

    1   Sleep disorders research center, Kermanshah University of Medical Sciences, Kermanshah, Iran.

  • Habibolah Khazaie

    1   Sleep disorders research center, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Weitere Informationen
Auch verfügbar auf
  Lizenzen und Reprints

Objective Second generation (atypical) antipsychotics are increasingly being used for treatment of insomnia, but there is little evidence to show long-term efficacy of these medication. This follow-up study was designed to assess patients with chronic insomnia who were treated with atypical antipsychotics.

Material and Methods In this follow-up study, forty patients with chronic insomnia were evaluated between 2016 and 2018 following after one year of treatment with two atypical antipsychotic drugs of olanzapine and quetiapine in two groups in the sleep disorders research center of Kermanshah University of Medical Science in Iran. The Pittsburgh Sleep Quality Questionnaire (PSQI) and 5 consecutive nights of Actigraphy were utilized to evaluate both subjective and objective measures of sleep quality. Lastly, sleep quality before and after treatment and comparisons of sleep quality between the two groups were performed.

Results Nine male participants comprised olanzapine group (n=22) and six male participants comprised the quetiapine group (n=18). The average age in the olanzapine group was 45.23±10.18 and the average age in the quetiapine group was 46.33±7.99. Results showed total PSQI score improved significantly in both groups (p<0.05), while the actigraphy results showed only significant improvement in sleep quality parameters in the quetiapine group (p<0.05).

Conclusion Two atypical antipsychotics drugs of olanzapine and quetiapine have long-term efficacy in managing chronic insomnia. More improvements in objective sleep quality with quetiapine is promising for patients with chronic insomnia. Further research to evaluate long-term adverse effects of atypical antipsychotic drugs is recommended.

Chronic Insomnia - Sleep Quality - Atypical Antipsychotics

FINANCIAL SUPPORT

This study was funded by Research Organization of Kermanshah University of Medical Sciences




Publikationsverlauf

Eingereicht: 18. Februar 2020

Angenommen: 15. Mai 2020

Artikel online veröffentlicht:
30. November 2023

© 2023. Brazilian Sleep Association. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • REFERENCES

  • 1 Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD. Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2016 Jul;165(2):125-33.
  • 2 Ancoli-Israel S. The impact and prevalence of chronic insomnia and other sleep disturbances associated with chronic illness. Am J Manag Care. 2006 May;12(8 Suppl):S221-9.
  • 3 Taylor DJ, Lichstein KL, Durrence HH. Insomnia as a health risk factor. Behav Sleep Med. 2003;1(4):227-47.
  • 4 Li Y, Zhang X, Winkelman JW, Redline S, Hu FB, Stampfer M, et al. Association between insomnia symptoms and mortality: a prospective study of US men. Circulation. 2014 Feb;129(7):737-46.
  • 5 Khazaie H, Rezaie L, Darvishi F, Najafi F, Avis K. Treatment of paradoxical insomnia with atypical antipsychotic drugs. A comparison of olanzapine and risperidone. Neurosciences (Riyadh). 2013 Jan;18(1):64-9.
  • 6 Cheung JM, Atternäs K, Melchior M, Marshall NS, Fois RA, Saini B. Primary health care practitioner perspectives on the management of insomnia: a pilot study. Aust J Prim Health. 2014 Dec;20(1):103-12.
  • 7 Roehrs T, Roth T. ‘Hypnotic’ prescription patterns in a large managedcare population. Sleep Med. 2004 Sep;5(5):463-6.
  • 8 Yi XY, Ni SF, Ghadami MR, Meng HQ, Chen MY, Kuang L, et al. Trazodone for the treatment of insomnia: a meta-analysis of randomized placebo-controlled trials. Sleep Med. 2018 May;45:25-32.
  • 9 Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2017 Jun;13(2):307-49.
  • 10 Wiegand MH, Landry F, Brückner T, Pohl C, Veseli Z, Jahn T. Quetiapine in primary insomnia: a pilot study. Psychopharmacology. 2008 Feb;196(2):337-8.
  • 11 Thompson W, Quay TAW, Rojas-Fernandez C, Farrell B, Bjerre LM. Atypical antipsychotics for insomnia: a systematic review. Sleep Med. 2016 May;22:13-7.
  • 12 Khazaie H, Rezaei L, Tahmasian M, Ahmadi A, Schwebel D, Russo M. Insomnia treatment by olanzapine: is sleep state misperception a psychotic disorder?. Sleep Med. 2009 Apr;15(2):110-2.
  • 13 Farrahi J, Nakhaee N, Sheibani V, Garrusi B, Amirkafi A. Psychometric properties of the Persian version of the Pittsburgh Sleep Quality Index addendum for PTSD (PSQI-A). Sleep Breath. 2009 Aug;13(3):259-62.
  • 14 Tahmasian M, Khazaie H, Sepehry AA, Russo MB. Ambulatory monitoring of sleep disorders. J Pak Med Assoc. 2010 Jun;60(6):480-7.
  • 15 Juri C, Chaná P, Tapia J, Kunstmann C, Parrao T. Quetiapine for insomnia in Parkinson disease: results from an open-label trial. Clin Neuropharmacol. 2005 Jul/Aug;28(4):185-7.
  • 16 Ringman JM, Schneider L. Treatment options for agitation in dementia. Curr Treat Options Neurol. 2019 Jun;21(7):30.
  • 17 Kluge M, Schacht A, Himmerich H, Rummel-Kluge C, Wehmeier PM, Dalal M, et al. Olanzapine and clozapine differently affect sleep in patients with schizophrenia: results from a double-blind, polysomnographic study and review of the literature. Schizophr Res. 2014 Jan;152(1):255-60.
  • 18 Monti JM, Torterolo P, Perumal SRP. The effects of second generation antipsychotic drugs on sleep variables in healthy subjects and patients with schizophrenia. Sleep Med Rev. 2017 Jun;33:51-7.
  • 19 Giménez S, Clos S, Romero S, Grasa E, Morte A, Barbanoj MJ. Effects of olanzapine, risperidone and haloperidol on sleep after a single oral morning dose in healthy volunteers. Psychopharmacology. 2007 Mar;190(4):507-16.
  • 20 Khazaie H, Zakiei A. Efficacy of acceptance and commitment therapy on emotional dysregulation and sleep quality in patients with chronic insomnia. J Mazandaran Univ Med Sci. 2019;29(178):52-63.